Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):858–864. doi: 10.1054/bjoc.1999.1012

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

P Garnero 1,2, N Buchs 3, J Zekri 4, R Rizzoli 3, R E Coleman 4, P D Delmas 1
PMCID: PMC2374389  PMID: 10732759

Abstract

Although increased bone formation is a prominent feature of patients with osteosclerotic metastases from prostate cancer, there is also some evidence for increased bone resorption. The aim of this study was to compare the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment. Thirty-nine patients with prostate cancer and bone metastasis, nine patients with prostate cancer without bone metastases, nine patients with benign prostatic hyperplasia and 355 healthy age-matched men were included. Urinary non-isomerized (α CTX) and β isomerized (β CTX) type I collagen C-telopeptides (CTX) and a new assay for serum CTX were used to assess bone resorption. Bone formation was determined by serum osteocalcin, serum total (T-ALP) and bone (BAP) alkaline phosphatase and serum type I collagen C-terminal propeptide (PICP). Fourteen patients with bone metastases were also evaluated 15 days after a single injection of the bisphosphonate pamidronate (120 mg). Levels of all bone formation and bone resorption markers were significantly (P< 0.006–0.0001) higher in patients with prostate cancer and bone metastasis than in patients with benign prostatic hyperplasia, patients with prostate cancer without bone metastases and healthy controls. In patients with bone metastases the median was increased by 67% for serum osteocalcin, 128% for T-ALP, 138% for BAP, 79% for PICP, 220% for urinary α CTX, 149% for urinary β CTX and 214% for serum CTX. After bisphosphonate treatment all three resorption markers significantly decreased by an average of 65% (P = 0.001), 71% (P = 0.0010) and 61% (P = 0.0015) for urinary α CTX, urinary β CTX and serum CTX, respectively, whereas no significant change was observed for any bone formation markers. Patients with prostate cancer and bone metastases exhibit a marked increase in bone resorption, which decreases within a few days of treatment with pamidronate. These findings suggest that these new resorption markers may be useful for the management of these patients. © 2000 Cancer Research Campaign

Keywords: bone markers, prostate cancer, bone metastases, type I collagen, bisphosphonate

Full Text

The Full Text of this article is available as a PDF (115.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1674–1679. doi: 10.1002/(sici)1097-0142(19971015)80:8+<1674::aid-cncr18>3.3.co;2-d. [DOI] [PubMed] [Google Scholar]
  2. Adami S., Salvagno G., Guarrera G., Bianchi G., Dorizzi R., Rosini S., Mobilio G., Lo Cascio V. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152–1154. doi: 10.1016/s0022-5347(17)47663-4. [DOI] [PubMed] [Google Scholar]
  3. Akimoto S., Furuya Y., Akakura K., Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J. 1998 Feb;45(1):97–104. doi: 10.1507/endocrj.45.97. [DOI] [PubMed] [Google Scholar]
  4. Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. J. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 Feb 22;334(8):488–493. doi: 10.1056/NEJM199602223340802. [DOI] [PubMed] [Google Scholar]
  5. Berruti A., Piovesan A., Torta M., Raucci C. A., Gorzegno G., Paccotti P., Dogliotti L., Angeli A. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer. 1996 Jun;73(12):1581–1587. doi: 10.1038/bjc.1996.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Blom E., Ali M. M., Mortensen B., Huseby N. E. Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates. Clin Chim Acta. 1998 Feb 23;270(2):125–137. doi: 10.1016/s0009-8981(97)00217-9. [DOI] [PubMed] [Google Scholar]
  7. Body J. J., Coleman R. E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996 Jul;22(4):265–287. doi: 10.1016/s0305-7372(96)90020-1. [DOI] [PubMed] [Google Scholar]
  8. Bonde M., Fledelius C., Qvist P., Christiansen C. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption. Clin Chem. 1996 Oct;42(10):1639–1644. [PubMed] [Google Scholar]
  9. Bonde M., Garnero P., Fledelius C., Qvist P., Delmas P. D., Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res. 1997 Jul;12(7):1028–1034. doi: 10.1359/jbmr.1997.12.7.1028. [DOI] [PubMed] [Google Scholar]
  10. Bonde M., Qvist P., Fledelius C., Riis B. J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994 Nov;40(11 Pt 1):2022–2025. [PubMed] [Google Scholar]
  11. Carey P. O., Lippert M. C. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 1988 Nov;32(5):403–407. doi: 10.1016/0090-4295(88)90410-4. [DOI] [PubMed] [Google Scholar]
  12. Clarke N. W., McClure J., George N. J. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992 Jan;69(1):64–70. doi: 10.1111/j.1464-410x.1992.tb15461.x. [DOI] [PubMed] [Google Scholar]
  13. Clarke N. W., McClure J., George N. J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991 Jul;68(1):74–80. doi: 10.1111/j.1464-410x.1991.tb15260.x. [DOI] [PubMed] [Google Scholar]
  14. Coleman R. E. Monitoring of bone metastases. Eur J Cancer. 1998 Feb;34(2):252–259. doi: 10.1016/s0959-8049(97)10134-4. [DOI] [PubMed] [Google Scholar]
  15. Delmas P. D., Demiaux B., Malaval L., Chapuy M. C., Meunier P. J. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int. 1986 Jan;38(1):60–61. doi: 10.1007/BF02556596. [DOI] [PubMed] [Google Scholar]
  16. Elomaa I., Kylmälä T., Tammela T., Viitanen J., Ottelin J., Ruutu M., Jauhiainen K., Ala-Opas M., Roos L., Seppänen J. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer. Int Urol Nephrol. 1992;24(2):159–166. doi: 10.1007/BF02549644. [DOI] [PubMed] [Google Scholar]
  17. Engler H., Koeberle D., Thuerlimann B., Senn H. J., Riesen W. F. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clin Chem Lab Med. 1998 Nov;36(11):879–885. doi: 10.1515/CCLM.1998.154. [DOI] [PubMed] [Google Scholar]
  18. Fledelius C., Johnsen A. H., Cloos P. A., Bonde M., Qvist P. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem. 1997 Apr 11;272(15):9755–9763. doi: 10.1074/jbc.272.15.9755. [DOI] [PubMed] [Google Scholar]
  19. Garnero P., Fledelius C., Gineyts E., Serre C. M., Vignot E., Delmas P. D. Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res. 1997 Sep;12(9):1407–1415. doi: 10.1359/jbmr.1997.12.9.1407. [DOI] [PubMed] [Google Scholar]
  20. Garnero P., Gineyts E., Schaffer A. V., Seaman J., Delmas P. D. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998 Feb;41(2):354–360. doi: 10.1002/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  21. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P. D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res. 1992 Dec;7(12):1389–1398. doi: 10.1002/jbmr.5650071206. [DOI] [PubMed] [Google Scholar]
  22. Garnero P., Shih W. J., Gineyts E., Karpf D. B., Delmas P. D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994 Dec;79(6):1693–1700. doi: 10.1210/jcem.79.6.7989477. [DOI] [PubMed] [Google Scholar]
  23. Gomez B., Jr, Ardakani S., Ju J., Jenkins D., Cerelli M. J., Daniloff G. Y., Kung V. T. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem. 1995 Nov;41(11):1560–1566. [PubMed] [Google Scholar]
  24. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998 Jul;13(7):1124–1133. doi: 10.1359/jbmr.1998.13.7.1124. [DOI] [PubMed] [Google Scholar]
  25. Hassager C., Jensen L. T., Pødenphant J., Thomsen K., Christiansen C. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int. 1994 Jan;54(1):30–33. doi: 10.1007/BF00316286. [DOI] [PubMed] [Google Scholar]
  26. Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785–1791. doi: 10.1056/NEJM199612123352401. [DOI] [PubMed] [Google Scholar]
  27. Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996 Jan;77(1):102–106. doi: 10.1046/j.1464-410x.1996.82817.x. [DOI] [PubMed] [Google Scholar]
  28. Koizumi M., Maeda H., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Dissociation of bone formation markers in bone metastasis of prostate cancer. Br J Cancer. 1997;75(11):1601–1604. doi: 10.1038/bjc.1997.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kylmälä T., Tammela T. L., Risteli L., Risteli J., Kontturi M., Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995 May;71(5):1061–1064. doi: 10.1038/bjc.1995.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kylmälä T., Tammela T., Risteli L., Risteli J., Taube T., Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29A(6):821–825. doi: 10.1016/s0959-8049(05)80417-4. [DOI] [PubMed] [Google Scholar]
  31. Lorente J. A., Morote J., Raventos C., Encabo G., Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol. 1996 Apr;155(4):1348–1351. [PubMed] [Google Scholar]
  32. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997 Feb;157(2):539–543. [PubMed] [Google Scholar]
  33. Miyamoto K. K., McSherry S. A., Robins S. P., Besterman J. M., Mohler J. L. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol. 1994 Apr;151(4):909–913. doi: 10.1016/s0022-5347(17)35120-0. [DOI] [PubMed] [Google Scholar]
  34. Nakashima J., Sumitomo M., Miyajima A., Jitsukawa S., Saito S., Tachibana M., Murai M. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol. 1997 May;157(5):1736–1739. [PubMed] [Google Scholar]
  35. Nguyen-Pamart M., Caty A., Feutrie M. L., Fournier C., Gosselin P., Mazeman E. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Br J Urol. 1997 Sep;80(3):452–455. doi: 10.1046/j.1464-410x.1997.00375.x. [DOI] [PubMed] [Google Scholar]
  36. Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H. W., Schmidt H., Baumgartner G., Thiébaud D., Ludwig H., Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995 Jan;80(1):97–103. doi: 10.1210/jcem.80.1.7829646. [DOI] [PubMed] [Google Scholar]
  37. Pelger R. C., Hamdy N. A., Zwinderman A. H., Lycklama à Nijeholt A. A., Papapoulos S. E. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998 Apr;22(4):403–408. doi: 10.1016/s8756-3282(97)00289-5. [DOI] [PubMed] [Google Scholar]
  38. Pollen J. J., Witztum K. F., Ashburn W. L. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984 Apr;142(4):773–776. doi: 10.2214/ajr.142.4.773. [DOI] [PubMed] [Google Scholar]
  39. Price P. A., Williamson M. K., Lothringer J. W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981 Dec 25;256(24):12760–12766. [PubMed] [Google Scholar]
  40. Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993 Apr;39(4):635–640. [PubMed] [Google Scholar]
  41. Rosenquist C., Fledelius C., Christgau S., Pedersen B. J., Bonde M., Qvist P., Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998 Nov;44(11):2281–2289. [PubMed] [Google Scholar]
  42. Sano M., Kushida K., Takahashi M., Ohishi T., Kawana K., Okada M., Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br J Cancer. 1994 Oct;70(4):701–703. doi: 10.1038/bjc.1994.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Smedsrød B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J. 1990 Oct 15;271(2):345–350. doi: 10.1042/bj2710345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  45. Takeuchi S., Arai K., Saitoh H., Yoshida K., Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996 Nov;156(5):1691–1695. [PubMed] [Google Scholar]
  46. Taube T., Kylmälä T., Lamberg-Allardt C., Tammela T. L., Elomaa I. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study. Eur J Cancer. 1994;30A(6):751–758. doi: 10.1016/0959-8049(94)90287-9. [DOI] [PubMed] [Google Scholar]
  47. Uebelhart D., Gineyts E., Chapuy M. C., Delmas P. D. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990 Jan;8(1):87–96. doi: 10.1016/0169-6009(91)90143-n. [DOI] [PubMed] [Google Scholar]
  48. Urwin G. H., Percival R. C., Harris S., Beneton M. N., Williams J. L., Kanis J. A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985 Dec;57(6):721–723. doi: 10.1111/j.1464-410x.1985.tb07040.x. [DOI] [PubMed] [Google Scholar]
  49. Vinholes J. J., Purohit O. P., Abbey M. E., Eastell R., Coleman R. E. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997 Dec;8(12):1243–1250. doi: 10.1023/a:1008238422151. [DOI] [PubMed] [Google Scholar]
  50. Vinholes J., Guo C. Y., Purohit O. P., Eastell R., Coleman R. E. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996 May;73(9):1089–1095. doi: 10.1038/bjc.1996.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Yoshida K., Sumi S., Arai K., Koga F., Umeda H., Hosoya Y., Honda M., Yano M., Moriguchi H., Kitahara S. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer. 1997 Nov 1;80(9):1760–1767. [PubMed] [Google Scholar]
  52. Young G. P., Rose I. S., Cropper S., Seetharam S., Alpers D. H. Hepatic clearance of rat plasma intestinal alkaline phosphatase. Am J Physiol. 1984 Oct;247(4 Pt 1):G419–G426. doi: 10.1152/ajpgi.1984.247.4.G419. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES